KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 1, 2013, Pages 91-101

  Webster, Jennifer ^a   Kauffman, Tia L ^a   Feigelson, Heather Spencer ^b   Pawloski, Pamala A ^c   Onitilo, Adedayo A ^d   Potosky, Arnold L ^e   Cross, Deanna ^d   Meier, Paul R ^f   Mirabedi, Anousheh S ^g   Delate, Thomas ^b   Daida, Yihe ^h   Williams, Andrew E ^h   Alexander, Gwen L ^f   McCarty, Catherine A ^d,i   Honda, Stacey ^h   Kushi, Lawrence H ^g   Goddard, Katrina A B ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

^c HEALTHPARTNERS INSTITUTE   (United States)

^d MARSHFIELD CLINIC   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g DIVISION OF RESEARCH   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; COLORECTAL CANCER; COMORBIDITY; DISEASE SEVERITY; EDUCATIONAL STATUS; ELECTRONIC MEDICAL RECORD; ETHNICITY; FAMILY HISTORY; GENDER; GENETIC SCREENING; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; PATIENT CARE; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; RACE; SURVIVAL TIME; WILD TYPE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC TESTING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84872138820     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0545     Document Type: Article

References (25)

1. Blue Cross and Blue Shield Association. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. [cited 2012 Jan 4]. Available from: http://bcbs.com/blueresources/tec/vols/23/23-06. pdf.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
3. National Comprehensive Cancer Network. NCCN Updates Guidelines for Colorectal Cancer. [cited 2012 Jan 15]. Available from: http://www.nccn.org/ about/news/newsinfoasp?NewsID=194.
4. Engstrom P, Arnoletti J, Benson A, Chen Y, Choti M, Cooper H. Colon cancer clinical practice guidelines in oncology. J Natl Comprehensive Cancer Network 2009;7:778-831.
5. Engstrom P, Arnoletti J, Benson A, Chen Y, Choti M, Cooper H. Colon cancer clinical practice guidelines in oncology. [cited 2012 Jan 5]. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
6. US Food and Drug Administration. FDA prescribing information for Erbitux. [cited 2011 Dec 21]. Available from: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/125084s168lbl.pdf.
7. Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, et al. Building a research consortium of large health systems: The Cancer Research Network. J Natl Cancer Inst Monogr 2005:3-11.
8. US Department of Commerce - US Census Bureau. The 2012 Statistical Abstract; The National Data Book; Health & Nutrition: Health Insurance. [cited 2012 Aug 10]. Available from: http://www.census.gov/compendia/statab/ cats/health-nutrition/health-insurance.html.
9. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed., Chicago, IL [cited 2012 Aug 10]. Available from: http://www.cancerstaging.org/ products/pasteditions.html.
10. Hornbrook MC, Hart G, Ellis JL, Bachman DJ, Ansell G, Greene SM, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr 2005;12-25.
11. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
12. Feigelson HS, Rahm AK, Funk K, Kauffman T, Johnson M, Richards CS, et al. Validation of KRAS mutation testing across five certified laboratories. Clin Med Res 2011;9:141-86.
13. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
14. Ohta M, Seto M, Ijichi H, Miyabayashi K, Kudo Y, Mohri D, et al. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. Gastroenterology 2009;136:206-16.
15. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (May 20 suppl; abstr 2).
16. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26 (May 20 suppl; abstr 4000).
17. European Medicines Agency (EMEA).Summary of the European Public Assessment Report (EPAR) for Erbitux (cetuximab); explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. [cited 2012 Jan 20]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000558/human-med-000769.
18. Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, et al. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011;6:133-45.
19. Westfall JM, Mold J, Fagnan L. Practice-based research-"Blue Highways" on the NIH roadmap. JAMA 2007;297:403-6.
20. Levin LA, Danesh-Meyer HV. Lost in translation: bumps in the road between bench and bedside. JAMA 2010;303:1533-4.
21. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635-45.
22. Mouchawar J, Hensley-Alford S, Laurion S, Ellis J, Kulchak-Rahm A, Finucane ML, et al. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally-occurring experiment. Genet Med 2005;7:191-7.
23. Rahm AK, Sukhanova A, Ellis J, Mouchawar J. Increasing utilization of cancer genetic counseling services using a patient navigator model. J Genet Couns 2007;16:171-7.
24. Brooks L, Lennard F, Shenton A, Lalloo F, Ambus I, Ardern-Jones A, et al. BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet 2004;12:654-62.
25. Julian-Reynier C, Sobol H, Sevilla C, Nogues C, Bourret P. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. French Cancer Genetic Network. Psychooncology 2000;9:504-10.